Suplementary Table 1.
Enrichment of NMOSD-associated miRNAs in the molecular pathways.
| MiRNA | PathName | PathFg | PathBg | GenomeFG | GenomeBG | P value | BH |
|---|---|---|---|---|---|---|---|
| hsa-miR-101-5p | Insulin signaling pathway | 87 | 139 | 8485 | 19747 | 2.34E-06 | 0.00045371 |
| hsa-miR-101-5p | Endocytosis | 109 | 187 | 8485 | 19747 | 1.65E-05 | 0.003114265 |
| hsa-miR-101-5p | Long term potentiation | 48 | 71 | 8485 | 19747 | 2.36E-05 | 0.004468536 |
| hsa-miR-101-5p | Colorectal cancer | 56 | 86 | 8485 | 19747 | 2.78E-05 | 0.005217761 |
| hsa-miR-101-5p | Neurotrophin signaling pathway | 78 | 129 | 8485 | 19747 | 4.52E-05 | 0.008402147 |
| hsa-miR-101-5p | Glioma | 44 | 65 | 8485 | 19747 | 4.89E-05 | 0.009095575 |
| hsa-miR-101-5p | Adherens junction | 50 | 76 | 8485 | 19747 | 4.92E-05 | 0.009146105 |
| hsa-miR-101-5p | Pathways in cancer | 176 | 330 | 8485 | 19747 | 8.55E-05 | 0.015646108 |
| hsa-miR-101-5p | Endometrial cancer | 36 | 52 | 8485 | 19747 | 0.000115328 | 0.020759015 |
| hsa-miR-101-5p | Wnt signaling pathway | 88 | 152 | 8485 | 19747 | 0.000143178 | 0.025628775 |
| hsa-miR-101-5p | Axon guidance | 76 | 129 | 8485 | 19747 | 0.000185502 | 0.032833892 |
| hsa-miR-101-5p | T cell receptor signaling pathway | 66 | 110 | 8485 | 19747 | 0.000231552 | 0.040753187 |
| hsa-miR-101-5p | ErbB signaling pathway | 55 | 89 | 8485 | 19747 | 0.000260331 | 0.045557925 |
| hsa-miR-101-5p | Chronic myeloid leukemia | 47 | 75 | 8485 | 19747 | 0.000452969 | 0.077910691 |
| hsa-miR-101-5p | Phosphatidylinositol signaling system | 47 | 76 | 8485 | 19747 | 0.000695386 | 0.117520317 |
| hsa-miR-101-5p | Calcium signaling pathway | 98 | 178 | 8485 | 19747 | 0.000741421 | 0.125300102 |
| hsa-miR-101-5p | Chemokine signaling pathway | 103 | 189 | 8485 | 19747 | 0.000887525 | 0.148216608 |
| hsa-miR-101-5p | Ubiquitin mediated proteolysis | 76 | 134 | 8485 | 19747 | 0.000905223 | 0.151172313 |
| hsa-miR-101-5p | Melanoma | 44 | 71 | 8485 | 19747 | 0.000956101 | 0.158712713 |
| hsa-miR-101-5p | Renal cell carcinoma | 44 | 71 | 8485 | 19747 | 0.000956101 | 0.158712713 |
| hsa-miR-101-5p | Non small cell lung cancer | 35 | 54 | 8485 | 19747 | 0.000981599 | 0.16294541 |
| hsa-miR-101-5p | B cell receptor signaling pathway | 46 | 75 | 8485 | 19747 | 0.001018064 | 0.167980536 |
| hsa-miR-101-5p | Type II diabetes mellitus | 32 | 49 | 8485 | 19747 | 0.001327476 | 0.215051074 |
| hsa-miR-101-5p | mTOR signaling pathway | 34 | 53 | 8485 | 19747 | 0.001507004 | 0.241366957 |
| hsa-miR-101-5p | Gap junction | 53 | 90 | 8485 | 19747 | 0.001672357 | 0.265904786 |
| hsa-miR-101-5p | Prostate cancer | 52 | 89 | 8485 | 19747 | 0.002335429 | 0.361991448 |
| hsa-miR-101-5p | Fc gamma R mediated phagocytosis | 56 | 97 | 8485 | 19747 | 0.00236227 | 0.366151908 |
| hsa-miR-101-5p | Adipocytokine signaling pathway | 42 | 70 | 8485 | 19747 | 0.00300524 | 0.453791189 |
| hsa-miR-101-5p | MAPK signaling pathway | 139 | 272 | 8485 | 19747 | 0.003964632 | 0.582800901 |
| hsa-miR-101-5p | Pancreatic cancer | 44 | 75 | 8485 | 19747 | 0.004398819 | 0.637828798 |
| hsa-miR-101-5p | Focal adhesion | 106 | 203 | 8485 | 19747 | 0.004776226 | 0.687776614 |
| hsa-miR-101-5p | Purine metabolism | 84 | 158 | 8485 | 19747 | 0.006105552 | 0.844734415 |
| hsa-miR-101-5p | GnRH signaling pathway | 58 | 105 | 8485 | 19747 | 0.00745423 | 0.994695317 |
| hsa-miR-101-5p | Long term depression | 40 | 73 | 8485 | 19747 | 0.027582947 | 1 |
| hsa-miR-101-5p | Jak STAT signaling pathway | 82 | 156 | 8485 | 19747 | 0.009686644 | 1 |
| hsa-miR-101-5p | Small cell lung cancer | 46 | 84 | 8485 | 19747 | 0.019339805 | 1 |
| hsa-miR-101-5p | SNARE interactions in vesicular transport | 23 | 39 | 8485 | 19747 | 0.032118483 | 1 |
| hsa-miR-101-5p | Acute myeloid leukemia | 34 | 58 | 8485 | 19747 | 0.011708417 | 1 |
| hsa-miR-101-5p | Vascular smooth muscle contraction | 59 | 116 | 8485 | 19747 | 0.052274252 | 1 |
| hsa-miR-101-5p | Thyroid cancer | 19 | 29 | 8485 | 19747 | 0.011984069 | 1 |
| hsa-miR-101-5p | Lysine degradation | 27 | 45 | 8485 | 19747 | 0.015826415 | 1 |
| hsa-miR-101-5p | Epithelial cell signaling in Helicobacter pylori infection | 38 | 71 | 8485 | 19747 | 0.047178139 | 1 |
| hsa-miR-101-5p | Metabolic pathways | 499 | 1091 | 8485 | 19747 | 0.030975475 | 1 |
| hsa-miR-101-5p | VEGF signaling pathway | 44 | 78 | 8485 | 19747 | 0.011418856 | 1 |
| hsa-miR-101-5p | Fc epsilon RI signaling pathway | 43 | 82 | 8485 | 19747 | 0.052777799 | 1 |
| hsa-miR-101-5p | Amyotrophic lateral sclerosis ALS | 30 | 55 | 8485 | 19747 | 0.055429268 | 1 |
| hsa-miR-101-5p | Primary bile acid biosynthesis | 11 | 16 | 8485 | 19747 | 0.033948998 | 1 |
| hsa-miR-101-5p | Nicotinate and nicotinamide metabolism | 16 | 24 | 8485 | 19747 | 0.01649091 | 1 |
| hsa-miR-101-5p | Non homologous end joining | 10 | 13 | 8485 | 19747 | 0.014005601 | 1 |
| hsa-miR-101-5p | Inositol phosphate metabolism | 32 | 54 | 8485 | 19747 | 0.01154892 | 1 |
| hsa-miR-101-5p | Peroxisome | 44 | 79 | 8485 | 19747 | 0.015200198 | 1 |
| hsa-miR-101-5p | PPAR signaling pathway | 39 | 70 | 8485 | 19747 | 0.021327693 | 1 |
| hsa-miR-101-5p | Cell adhesion molecules CAMs | 67 | 133 | 8485 | 19747 | 0.050655518 | 1 |
| hsa-miR-101-5p | Nitrogen metabolism | 16 | 23 | 8485 | 19747 | 0.009100855 | 1 |
| hsa-miR-101-5p | Aldosterone regulated sodium reabsorption | 24 | 42 | 8485 | 19747 | 0.045107589 | 1 |
| hsa-miR-101-5p | O Glycan biosynthesis | 20 | 30 | 8485 | 19747 | 0.007542929 | 1 |
| hsa-miR-101-5p | Melanogenesis | 54 | 102 | 8485 | 19747 | 0.026728523 | 1 |
| hsa-miR-101-5p | Lysosome | 62 | 121 | 8485 | 19747 | 0.040474391 | 1 |
| hsa-miR-101-5p | Tight junction | 68 | 132 | 8485 | 19747 | 0.029075318 | 1 |
| hsa-miR-101-5p | Regulation of actin cytoskeleton | 103 | 212 | 8485 | 19747 | 0.056232548 | 1 |
| hsa-miR-101-5p | TGF beta signaling pathway | 46 | 86 | 8485 | 19747 | 0.031594456 | 1 |
| hsa-miR-126-5p | Pathways in cancer | 176 | 330 | 8124 | 19747 | 4.43E-06 | 0.000855946 |
| hsa-miR-126-5p | Small cell lung cancer | 55 | 84 | 8124 | 19747 | 5.61E-06 | 0.001083654 |
| hsa-miR-126-5p | Neurotrophin signaling pathway | 76 | 129 | 8124 | 19747 | 3.35E-05 | 0.006370669 |
| hsa-miR-126-5p | Colorectal cancer | 54 | 86 | 8124 | 19747 | 4.05E-05 | 0.007697755 |
| hsa-miR-126-5p | Chronic myeloid leukemia | 48 | 75 | 8124 | 19747 | 5.29E-05 | 0.01004258 |
| hsa-miR-126-5p | Apoptosis | 53 | 87 | 8124 | 19747 | 0.000151403 | 0.027706725 |
| hsa-miR-126-5p | Ubiquitin mediated proteolysis | 76 | 134 | 8124 | 19747 | 0.000189394 | 0.034280231 |
| hsa-miR-126-5p | Insulin signaling pathway | 78 | 139 | 8124 | 19747 | 0.000249692 | 0.044445215 |
| hsa-miR-126-5p | Pentose and glucuronate interconversions | 21 | 28 | 8124 | 19747 | 0.000289367 | 0.051279554 |
| hsa-miR-126-5p | ErbB signaling pathway | 53 | 89 | 8124 | 19747 | 0.00034132 | 0.060413711 |
| hsa-miR-126-5p | Non small cell lung cancer | 35 | 54 | 8124 | 19747 | 0.000373669 | 0.065765685 |
| hsa-miR-126-5p | MAPK signaling pathway | 139 | 272 | 8124 | 19747 | 0.000528068 | 0.092411913 |
| hsa-miR-126-5p | Glioma | 40 | 65 | 8124 | 19747 | 0.000709157 | 0.123393247 |
| hsa-miR-126-5p | Ascorbate and aldarate metabolism | 19 | 26 | 8124 | 19747 | 0.000976366 | 0.168911356 |
| hsa-miR-126-5p | p53 signaling pathway | 41 | 68 | 8124 | 19747 | 0.001096874 | 0.189759278 |
| hsa-miR-126-5p | Endocytosis | 98 | 187 | 8124 | 19747 | 0.001158089 | 0.200349415 |
| hsa-miR-126-5p | Type II diabetes mellitus | 31 | 49 | 8124 | 19747 | 0.001447572 | 0.247534873 |
| hsa-miR-126-5p | Prostate cancer | 51 | 89 | 8124 | 19747 | 0.001488647 | 0.254558697 |
| hsa-miR-126-5p | Pancreatic cancer | 44 | 75 | 8124 | 19747 | 0.001614467 | 0.274459422 |
| hsa-miR-126-5p | Renal cell carcinoma | 42 | 71 | 8124 | 19747 | 0.001632088 | 0.277455025 |
| hsa-miR-126-5p | T cell receptor signaling pathway | 61 | 110 | 8124 | 19747 | 0.001662737 | 0.282665317 |
| hsa-miR-126-5p | Axon guidance | 70 | 129 | 8124 | 19747 | 0.001728524 | 0.293849129 |
| hsa-miR-126-5p | Wnt signaling pathway | 79 | 152 | 8124 | 19747 | 0.004369155 | 0.642265816 |
| hsa-miR-126-5p | Melanoma | 40 | 71 | 8124 | 19747 | 0.00685062 | 0.897431176 |
| hsa-miR-126-5p | Focal adhesion | 101 | 203 | 8124 | 19747 | 0.007764884 | 0.978375349 |
| hsa-miR-126-5p | VEGF signaling pathway | 41 | 78 | 8124 | 19747 | 0.027028017 | 1 |
| hsa-miR-126-5p | ECM receptor interaction | 43 | 84 | 8124 | 19747 | 0.039640345 | 1 |
| hsa-miR-126-5p | GnRH signaling pathway | 52 | 105 | 8124 | 19747 | 0.05015675 | 1 |
| hsa-miR-126-5p | Progesterone mediated oocyte maturation | 44 | 88 | 8124 | 19747 | 0.057399498 | 1 |
| hsa-miR-126-5p | ABC transporters | 26 | 44 | 8124 | 19747 | 0.012230769 | 1 |
| hsa-miR-126-5p | Endometrial cancer | 28 | 52 | 8124 | 19747 | 0.043389343 | 1 |
| hsa-miR-126-5p | Non homologous end joining | 9 | 13 | 8124 | 19747 | 0.038757914 | 1 |
| hsa-miR-126-5p | Adipocytokine signaling pathway | 39 | 70 | 8124 | 19747 | 0.009610695 | 1 |
| hsa-miR-126-5p | B cell receptor signaling pathway | 39 | 75 | 8124 | 19747 | 0.037002266 | 1 |
| hsa-miR-126-5p | Primary immunodeficiency | 20 | 35 | 8124 | 19747 | 0.040787619 | 1 |
| hsa-miR-126-5p | Cell adhesion molecules CAMs | 68 | 133 | 8124 | 19747 | 0.012382036 | 1 |
| hsa-miR-126-5p | Cell cycle | 64 | 124 | 8124 | 19747 | 0.011604645 | 1 |
| hsa-miR-126-5p | Acute myeloid leukemia | 31 | 58 | 8124 | 19747 | 0.038959432 | 1 |
| hsa-miR-126-5p | Drug metabolism other enzymes | 29 | 51 | 8124 | 19747 | 0.016791375 | 1 |
| hsa-miR-126-5p | PPAR signaling pathway | 36 | 70 | 8124 | 19747 | 0.052375031 | 1 |
| hsa-miR-126-5p | Starch and sucrose metabolism | 29 | 52 | 8124 | 19747 | 0.023271708 | 1 |
| hsa-miR-126-5p | mTOR signaling pathway | 29 | 53 | 8124 | 19747 | 0.03154144 | 1 |
| hsa-miR-126-5p | Aldosterone regulated sodium reabsorption | 25 | 42 | 8124 | 19747 | 0.012305735 | 1 |
| hsa-miR-126-5p | Tight junction | 64 | 132 | 8124 | 19747 | 0.052078934 | 1 |
| hsa-miR-126-5p | Porphyrin and chlorophyll metabolism | 25 | 41 | 8124 | 19747 | 0.008117058 | 1 |
| hsa-miR-126-5p | Regulation of actin cytoskeleton | 99 | 212 | 8124 | 19747 | 0.057272856 | 1 |
| hsa-miR-126-5p | Protein export | 14 | 23 | 8124 | 19747 | 0.044570896 | 1 |
| hsa-miR-22-5p | Pathways in cancer | 257 | 330 | 11812 | 19747 | 1.83E-12 | 3.56E-10 |
| hsa-miR-22-5p | Axon guidance | 110 | 129 | 11812 | 19747 | 2.59E-10 | 5.00E-08 |
| hsa-miR-22-5p | Endocytosis | 149 | 187 | 11812 | 19747 | 4.95E-09 | 9.40E-07 |
| hsa-miR-22-5p | Wnt signaling pathway | 124 | 152 | 11812 | 19747 | 6.55E-09 | 1.24E-06 |
| hsa-miR-22-5p | MAPK signaling pathway | 207 | 272 | 11812 | 19747 | 8.91E-09 | 1.69E-06 |
| hsa-miR-22-5p | Colorectal cancer | 75 | 86 | 11812 | 19747 | 2.35E-08 | 4.45E-06 |
| hsa-miR-22-5p | Cell adhesion molecules CAMs | 108 | 133 | 11812 | 19747 | 9.92E-08 | 1.85E-05 |
| hsa-miR-22-5p | ErbB signaling pathway | 76 | 89 | 11812 | 19747 | 1.37E-07 | 2.56E-05 |
| hsa-miR-22-5p | Neurotrophin signaling pathway | 103 | 129 | 11812 | 19747 | 9.50E-07 | 0.000173927 |
| hsa-miR-22-5p | Focal adhesion | 154 | 203 | 11812 | 19747 | 9.68E-07 | 0.000177219 |
| hsa-miR-22-5p | Chronic myeloid leukemia | 64 | 75 | 11812 | 19747 | 1.43E-06 | 0.000260548 |
| hsa-miR-22-5p | Small cell lung cancer | 70 | 84 | 11812 | 19747 | 2.90E-06 | 0.000522275 |
| hsa-miR-22-5p | Glioma | 56 | 65 | 11812 | 19747 | 3.48E-06 | 0.000622806 |
| hsa-miR-22-5p | Type II diabetes mellitus | 44 | 49 | 11812 | 19747 | 3.52E-06 | 0.000629532 |
| hsa-miR-22-5p | B cell receptor signaling pathway | 63 | 75 | 11812 | 19747 | 5.33E-06 | 0.000948843 |
| hsa-miR-22-5p | Prostate cancer | 73 | 89 | 11812 | 19747 | 5.80E-06 | 0.00102714 |
| hsa-miR-22-5p | T cell receptor signaling pathway | 87 | 110 | 11812 | 19747 | 1.34E-05 | 0.002351804 |
| hsa-miR-22-5p | Leukocyte transendothelial migration | 91 | 116 | 11812 | 19747 | 1.57E-05 | 0.002744659 |
| hsa-miR-22-5p | Regulation of actin cytoskeleton | 156 | 212 | 11812 | 19747 | 1.73E-05 | 0.003024113 |
| hsa-miR-22-5p | Apoptosis | 70 | 87 | 11812 | 19747 | 3.23E-05 | 0.005550083 |
| hsa-miR-22-5p | Adherens junction | 62 | 76 | 11812 | 19747 | 4.08E-05 | 0.006975744 |
| hsa-miR-22-5p | Pancreatic cancer | 61 | 75 | 11812 | 19747 | 5.61E-05 | 0.009538741 |
| hsa-miR-22-5p | Fc gamma R mediated phagocytosis | 76 | 97 | 11812 | 19747 | 8.38E-05 | 0.014085998 |
| hsa-miR-22-5p | Endometrial cancer | 44 | 52 | 11812 | 19747 | 0.000101849 | 0.017008724 |
| hsa-miR-22-5p | Ubiquitin mediated proteolysis | 101 | 134 | 11812 | 19747 | 0.000107433 | 0.017941347 |
| hsa-miR-22-5p | Insulin signaling pathway | 104 | 139 | 11812 | 19747 | 0.00014148 | 0.023485705 |
| hsa-miR-22-5p | Non small cell lung cancer | 45 | 54 | 11812 | 19747 | 0.000179093 | 0.029550271 |
| hsa-miR-22-5p | Melanogenesis | 78 | 102 | 11812 | 19747 | 0.000288309 | 0.047282657 |
| hsa-miR-22-5p | VEGF signaling pathway | 61 | 78 | 11812 | 19747 | 0.000454736 | 0.073212496 |
| hsa-miR-22-5p | Acute myeloid leukemia | 47 | 58 | 11812 | 19747 | 0.000474205 | 0.076346974 |
| hsa-miR-22-5p | p53 signaling pathway | 54 | 68 | 11812 | 19747 | 0.000481292 | 0.077197402 |
| hsa-miR-22-5p | Dorso ventral axis formation | 22 | 24 | 11812 | 19747 | 0.000620089 | 0.098594229 |
| hsa-miR-22-5p | Melanoma | 55 | 71 | 11812 | 19747 | 0.001297563 | 0.197229622 |
| hsa-miR-22-5p | Calcium signaling pathway | 125 | 178 | 11812 | 19747 | 0.002461358 | 0.356896943 |
| hsa-miR-22-5p | Long term potentiation | 54 | 71 | 11812 | 19747 | 0.002984255 | 0.426748527 |
| hsa-miR-22-5p | Renal cell carcinoma | 54 | 71 | 11812 | 19747 | 0.002984255 | 0.426748527 |
| hsa-miR-22-5p | Aldosterone regulated sodium reabsorption | 34 | 42 | 11812 | 19747 | 0.003015903 | 0.431274084 |
| hsa-miR-22-5p | Basal cell carcinoma | 43 | 55 | 11812 | 19747 | 0.003152907 | 0.447712777 |
| hsa-miR-22-5p | Amyotrophic lateral sclerosis ALS | 43 | 55 | 11812 | 19747 | 0.003152907 | 0.447712777 |
| hsa-miR-22-5p | Lysine degradation | 36 | 45 | 11812 | 19747 | 0.003356409 | 0.476610046 |
| hsa-miR-22-5p | Adipocytokine signaling pathway | 53 | 70 | 11812 | 19747 | 0.003848062 | 0.542576696 |
| hsa-miR-22-5p | mTOR signaling pathway | 41 | 53 | 11812 | 19747 | 0.005514037 | 0.733366983 |
| hsa-miR-22-5p | Epithelial cell signaling in Helicobacter pylori infection | 53 | 71 | 11812 | 19747 | 0.006391491 | 0.824502359 |
| hsa-miR-22-5p | Hypertrophic cardiomyopathy HCM | 63 | 86 | 11812 | 19747 | 0.006423679 | 0.828654588 |
| hsa-miR-22-5p | Arrhythmogenic right ventricular cardiomyopathy ARVC | 55 | 74 | 11812 | 19747 | 0.006436624 | 0.830010217 |
| hsa-miR-22-5p | Chondroitin sulfate biosynthesis | 19 | 22 | 11812 | 19747 | 0.007196724 | 0.899590471 |
| hsa-miR-22-5p | Phosphatidylinositol signaling system | 56 | 76 | 11812 | 19747 | 0.0081223 | 0.966553692 |
| hsa-miR-22-5p | Prion diseases | 28 | 35 | 11812 | 19747 | 0.009551427 | 1 |
| hsa-miR-22-5p | Heparan sulfate biosynthesis | 21 | 26 | 11812 | 19747 | 0.020411929 | 1 |
| hsa-miR-22-5p | Fc epsilon RI signaling pathway | 58 | 82 | 11812 | 19747 | 0.026603879 | 1 |
| hsa-miR-22-5p | GnRH signaling pathway | 73 | 105 | 11812 | 19747 | 0.025144507 | 1 |
| hsa-miR-22-5p | Chemokine signaling pathway | 128 | 189 | 11812 | 19747 | 0.014802878 | 1 |
| hsa-miR-22-5p | N Glycan biosynthesis | 35 | 46 | 11812 | 19747 | 0.01561363 | 1 |
| hsa-miR-22-5p | TGF beta signaling pathway | 62 | 86 | 11812 | 19747 | 0.0120408 | 1 |
| hsa-miR-22-5p | Hedgehog signaling pathway | 40 | 56 | 11812 | 19747 | 0.048585074 | 1 |
| hsa-miR-22-5p | ABC transporters | 33 | 44 | 11812 | 19747 | 0.026093417 | 1 |
| hsa-miR-22-5p | Type I diabetes mellitus | 32 | 44 | 11812 | 19747 | 0.05300307 | 1 |
| hsa-miR-22-5p | Bladder cancer | 33 | 43 | 11812 | 19747 | 0.015183097 | 1 |
| hsa-miR-22-5p | Jak STAT signaling pathway | 108 | 156 | 11812 | 19747 | 0.009237744 | 1 |
| hsa-miR-22-5p | Valine leucine and isoleucine degradation | 33 | 45 | 11812 | 19747 | 0.04218212 | 1 |
| hsa-miR-22-5p | Long term depression | 51 | 73 | 11812 | 19747 | 0.049326477 | 1 |
| hsa-miR-22-5p | SNARE interactions in vesicular transport | 30 | 39 | 11812 | 19747 | 0.019292832 | 1 |
| hsa-miR-22-5p | Caffeine metabolism | 7 | 7 | 11812 | 19747 | 0.027380781 | 1 |
| hsa-miR-22-5p | Dilated cardiomyopathy | 67 | 94 | 11812 | 19747 | 0.013884057 | 1 |
| hsa-miR-22-5p | Progesterone mediated oocyte maturation | 61 | 88 | 11812 | 19747 | 0.04174596 | 1 |
| hsa-miR-30b-5p | Pathways in cancer | 156 | 330 | 6411 | 19747 | 1.23E-08 | 2.38E-06 |
| hsa-miR-30b-5p | Adherens junction | 46 | 76 | 6411 | 19747 | 4.52E-07 | 8.67E-05 |
| hsa-miR-30b-5p | Colorectal cancer | 49 | 86 | 6411 | 19747 | 2.38E-06 | 0.000450104 |
| hsa-miR-30b-5p | ErbB signaling pathway | 50 | 89 | 6411 | 19747 | 3.30E-06 | 0.000623737 |
| hsa-miR-30b-5p | Glioma | 39 | 65 | 6411 | 19747 | 4.53E-06 | 0.000851658 |
| hsa-miR-30b-5p | Ubiquitin mediated proteolysis | 68 | 134 | 6411 | 19747 | 8.38E-06 | 0.001567818 |
| hsa-miR-30b-5p | Non small cell lung cancer | 33 | 54 | 6411 | 19747 | 1.41E-05 | 0.002637103 |
| hsa-miR-30b-5p | Wnt signaling pathway | 73 | 152 | 6411 | 19747 | 4.52E-05 | 0.008184389 |
| hsa-miR-30b-5p | Pancreatic cancer | 41 | 75 | 6411 | 19747 | 5.81E-05 | 0.010463047 |
| hsa-miR-30b-5p | Chronic myeloid leukemia | 41 | 75 | 6411 | 19747 | 5.81E-05 | 0.010463047 |
| hsa-miR-30b-5p | Axon guidance | 63 | 129 | 6411 | 19747 | 7.86E-05 | 0.013994427 |
| hsa-miR-30b-5p | Phosphatidylinositol signaling system | 41 | 76 | 6411 | 19747 | 8.68E-05 | 0.015459153 |
| hsa-miR-30b-5p | Apoptosis | 45 | 87 | 6411 | 19747 | 0.000151014 | 0.026578382 |
| hsa-miR-30b-5p | MAPK signaling pathway | 117 | 272 | 6411 | 19747 | 0.000158251 | 0.02785209 |
| hsa-miR-30b-5p | Long term potentiation | 38 | 71 | 6411 | 19747 | 0.000193569 | 0.034068087 |
| hsa-miR-30b-5p | Melanoma | 38 | 71 | 6411 | 19747 | 0.000193569 | 0.034068087 |
| hsa-miR-30b-5p | Endocytosis | 84 | 187 | 6411 | 19747 | 0.000238243 | 0.041930686 |
| hsa-miR-30b-5p | Prostate cancer | 45 | 89 | 6411 | 19747 | 0.000295855 | 0.052070558 |
| hsa-miR-30b-5p | Neurotrophin signaling pathway | 60 | 129 | 6411 | 19747 | 0.000594457 | 0.099868714 |
| hsa-miR-30b-5p | Long term depression | 37 | 73 | 6411 | 19747 | 0.00092949 | 0.150577329 |
| hsa-miR-30b-5p | Amyotrophic lateral sclerosis ALS | 29 | 55 | 6411 | 19747 | 0.001463924 | 0.229836089 |
| hsa-miR-30b-5p | Regulation of actin cytoskeleton | 89 | 212 | 6411 | 19747 | 0.00218848 | 0.334837477 |
| hsa-miR-30b-5p | Renal cell carcinoma | 35 | 71 | 6411 | 19747 | 0.00233667 | 0.357510548 |
| hsa-miR-30b-5p | Melanogenesis | 47 | 102 | 6411 | 19747 | 0.002785731 | 0.42343105 |
| hsa-miR-30b-5p | Endometrial cancer | 27 | 52 | 6411 | 19747 | 0.002814214 | 0.424946331 |
| hsa-miR-30b-5p | Focal adhesion | 85 | 203 | 6411 | 19747 | 0.002953579 | 0.44599037 |
| hsa-miR-30b-5p | Gap junction | 42 | 90 | 6411 | 19747 | 0.003411486 | 0.511722866 |
| hsa-miR-30b-5p | Progesterone mediated oocyte maturation | 41 | 88 | 6411 | 19747 | 0.003926434 | 0.585346476 |
| hsa-miR-30b-5p | Acute myeloid leukemia | 29 | 58 | 6411 | 19747 | 0.004116963 | 0.613427489 |
| hsa-miR-30b-5p | Protein export | 14 | 23 | 6411 | 19747 | 0.004720087 | 0.703292942 |
| hsa-miR-30b-5p | O Glycan biosynthesis | 17 | 30 | 6411 | 19747 | 0.005327257 | 0.788434095 |
| hsa-miR-30b-5p | Arrhythmogenic right ventricular cardiomyopathy ARVC | 35 | 74 | 6411 | 19747 | 0.005487362 | 0.806642248 |
| hsa-miR-30b-5p | Inositol phosphate metabolism | 27 | 54 | 6411 | 19747 | 0.005531749 | 0.813167132 |
| hsa-miR-30b-5p | Aldosterone regulated sodium reabsorption | 22 | 42 | 6411 | 19747 | 0.005864446 | 0.862073569 |
| hsa-miR-30b-5p | mTOR signaling pathway | 26 | 53 | 6411 | 19747 | 0.008761618 | 1 |
| hsa-miR-30b-5p | Ascorbate and aldarate metabolism | 14 | 26 | 6411 | 19747 | 0.019511549 | 1 |
| hsa-miR-30b-5p | Type II diabetes mellitus | 24 | 49 | 6411 | 19747 | 0.011815574 | 1 |
| hsa-miR-30b-5p | p53 signaling pathway | 30 | 68 | 6411 | 19747 | 0.029133167 | 1 |
| hsa-miR-30b-5p | Small cell lung cancer | 38 | 84 | 6411 | 19747 | 0.009658053 | 1 |
| hsa-miR-30b-5p | T cell receptor signaling pathway | 47 | 110 | 6411 | 19747 | 0.015157895 | 1 |
| hsa-miR-30b-5p | Leukocyte transendothelial migration | 49 | 116 | 6411 | 19747 | 0.016941064 | 1 |
| hsa-miR-30b-5p | Cell adhesion molecules CAMs | 53 | 133 | 6411 | 19747 | 0.043304347 | 1 |
| hsa-miR-30b-5p | Vascular smooth muscle contraction | 50 | 116 | 6411 | 19747 | 0.010372332 | 1 |
| hsa-miR-30b-5p | Thyroid cancer | 16 | 29 | 6411 | 19747 | 0.009556352 | 1 |
| hsa-miR-30b-5p | Insulin signaling pathway | 59 | 139 | 6411 | 19747 | 0.008447402 | 1 |
| hsa-miR-30b-5p | ABC transporters | 20 | 44 | 6411 | 19747 | 0.048992968 | 1 |
| hsa-miR-30b-5p | TGF beta signaling pathway | 39 | 86 | 6411 | 19747 | 0.008411963 | 1 |
| hsa-miR-30b-5p | Tight junction | 55 | 132 | 6411 | 19747 | 0.016223801 | 1 |
| hsa-miR-30b-5p | Hypertrophic cardiomyopathy HCM | 36 | 86 | 6411 | 19747 | 0.042112097 | 1 |
| hsa-miR-30b-5p | Bladder cancer | 20 | 43 | 6411 | 19747 | 0.03804409 | 1 |
| hsa-miR-30b-5p | Fc gamma R mediated phagocytosis | 42 | 97 | 6411 | 19747 | 0.016262241 | 1 |
| hsa-miR-30b-5p | Dilated cardiomyopathy | 39 | 94 | 6411 | 19747 | 0.040911576 | 1 |
| hsa-miR-30b-5p | Calcium signaling pathway | 73 | 178 | 6411 | 19747 | 0.00990428 | 1 |
| hsa-miR-30b-5p | Fc epsilon RI signaling pathway | 37 | 82 | 6411 | 19747 | 0.011088588 | 1 |
| hsa-miR-660-5p | Chronic myeloid leukemia | 47 | 75 | 5834 | 19747 | 2.75E-09 | 5.30E-07 |
| hsa-miR-660-5p | Pathways in cancer | 145 | 330 | 5834 | 19747 | 1.63E-08 | 3.12E-06 |
| hsa-miR-660-5p | Glioma | 41 | 65 | 5834 | 19747 | 2.14E-08 | 4.08E-06 |
| hsa-miR-660-5p | Insulin signaling pathway | 71 | 139 | 5834 | 19747 | 7.71E-08 | 1.46E-05 |
| hsa-miR-660-5p | Apoptosis | 49 | 87 | 5834 | 19747 | 1.69E-07 | 3.19E-05 |
| hsa-miR-660-5p | MAPK signaling pathway | 119 | 272 | 5834 | 19747 | 4.01E-07 | 7.50E-05 |
| hsa-miR-660-5p | ErbB signaling pathway | 49 | 89 | 5834 | 19747 | 4.34E-07 | 8.11E-05 |
| hsa-miR-660-5p | Non small cell lung cancer | 33 | 54 | 5834 | 19747 | 1.44E-06 | 0.000268502 |
| hsa-miR-660-5p | Pancreatic cancer | 41 | 75 | 5834 | 19747 | 4.73E-06 | 0.000864782 |
| hsa-miR-660-5p | Renal cell carcinoma | 39 | 71 | 5834 | 19747 | 6.86E-06 | 0.001248947 |
| hsa-miR-660-5p | Wnt signaling pathway | 70 | 152 | 5834 | 19747 | 1.17E-05 | 0.002111246 |
| hsa-miR-660-5p | Adipocytokine signaling pathway | 38 | 70 | 5834 | 19747 | 1.30E-05 | 0.002331179 |
| hsa-miR-660-5p | Small cell lung cancer | 43 | 84 | 5834 | 19747 | 2.51E-05 | 0.004445646 |
| hsa-miR-660-5p | Neurotrophin signaling pathway | 60 | 129 | 5834 | 19747 | 3.33E-05 | 0.005852361 |
| hsa-miR-660-5p | Aldosterone regulated sodium reabsorption | 25 | 42 | 5834 | 19747 | 5.11E-05 | 0.008849739 |
| hsa-miR-660-5p | Prostate cancer | 44 | 89 | 5834 | 19747 | 6.07E-05 | 0.010434751 |
| hsa-miR-660-5p | Calcium signaling pathway | 77 | 178 | 5834 | 19747 | 6.61E-05 | 0.011367391 |
| hsa-miR-660-5p | Axon guidance | 59 | 129 | 5834 | 19747 | 7.01E-05 | 0.012062999 |
| hsa-miR-660-5p | Vascular smooth muscle contraction | 54 | 116 | 5834 | 19747 | 7.81E-05 | 0.01334723 |
| hsa-miR-660-5p | VEGF signaling pathway | 39 | 78 | 5834 | 19747 | 0.000114223 | 0.019189454 |
| hsa-miR-660-5p | Dilated cardiomyopathy | 45 | 94 | 5834 | 19747 | 0.000133217 | 0.022247276 |
| hsa-miR-660-5p | Hypertrophic cardiomyopathy HCM | 41 | 86 | 5834 | 19747 | 0.000290082 | 0.046703244 |
| hsa-miR-660-5p | Ether lipid metabolism | 21 | 36 | 5834 | 19747 | 0.000300946 | 0.048452314 |
| hsa-miR-660-5p | Adherens junction | 37 | 76 | 5834 | 19747 | 0.000335452 | 0.053672279 |
| hsa-miR-660-5p | Long term potentiation | 35 | 71 | 5834 | 19747 | 0.000356024 | 0.056963838 |
| hsa-miR-660-5p | Melanoma | 35 | 71 | 5834 | 19747 | 0.000356024 | 0.056963838 |
| hsa-miR-660-5p | Type II diabetes mellitus | 26 | 49 | 5834 | 19747 | 0.000474592 | 0.075460141 |
| hsa-miR-660-5p | T cell receptor signaling pathway | 49 | 110 | 5834 | 19747 | 0.000588087 | 0.092917806 |
| hsa-miR-660-5p | Colorectal cancer | 40 | 86 | 5834 | 19747 | 0.000640805 | 0.10124723 |
| hsa-miR-660-5p | Heparan sulfate biosynthesis | 16 | 26 | 5834 | 19747 | 0.000700414 | 0.110665477 |
| hsa-miR-660-5p | Phosphatidylinositol signaling system | 36 | 76 | 5834 | 19747 | 0.00077014 | 0.12091191 |
| hsa-miR-660-5p | Fc epsilon RI signaling pathway | 38 | 82 | 5834 | 19747 | 0.000942721 | 0.148007141 |
| hsa-miR-660-5p | Chondroitin sulfate biosynthesis | 14 | 22 | 5834 | 19747 | 0.000946761 | 0.148641411 |
| hsa-miR-660-5p | B cell receptor signaling pathway | 35 | 75 | 5834 | 19747 | 0.001262727 | 0.195722739 |
| hsa-miR-660-5p | GnRH signaling pathway | 46 | 105 | 5834 | 19747 | 0.001305999 | 0.202429883 |
| hsa-miR-660-5p | Glycerophospholipid metabolism | 33 | 70 | 5834 | 19747 | 0.001386882 | 0.214966783 |
| hsa-miR-660-5p | Endometrial cancer | 26 | 52 | 5834 | 19747 | 0.001513571 | 0.23460344 |
| hsa-miR-660-5p | alpha Linolenic acid metabolism | 12 | 19 | 5834 | 19747 | 0.002432594 | 0.36245658 |
| hsa-miR-660-5p | Acute myeloid leukemia | 27 | 58 | 5834 | 19747 | 0.004528781 | 0.638558156 |
| hsa-miR-660-5p | Ubiquitin mediated proteolysis | 54 | 134 | 5834 | 19747 | 0.004925757 | 0.689605994 |
| hsa-miR-660-5p | Tight junction | 53 | 132 | 5834 | 19747 | 0.005783875 | 0.798174774 |
| hsa-miR-660-5p | Regulation of actin cytoskeleton | 80 | 212 | 5834 | 19747 | 0.006113676 | 0.84368735 |
| hsa-miR-660-5p | mTOR signaling pathway | 24 | 53 | 5834 | 19747 | 0.010883105 | 1 |
| hsa-miR-660-5p | Oocyte meiosis | 43 | 112 | 5834 | 19747 | 0.027327133 | 1 |
| hsa-miR-660-5p | Cell adhesion molecules CAMs | 52 | 133 | 5834 | 19747 | 0.011277543 | 1 |
| hsa-miR-660-5p | Glycerolipid metabolism | 19 | 46 | 5834 | 19747 | 0.059110806 | 1 |
| hsa-miR-660-5p | Keratan sulfate biosynthesis | 8 | 15 | 5834 | 19747 | 0.045846187 | 1 |
| hsa-miR-660-5p | Gap junction | 35 | 90 | 5834 | 19747 | 0.035823644 | 1 |
| hsa-miR-660-5p | Chemokine signaling pathway | 67 | 189 | 5834 | 19747 | 0.045513457 | 1 |
| hsa-miR-660-5p | Melanogenesis | 40 | 102 | 5834 | 19747 | 0.022771607 | 1 |
| hsa-miR-660-5p | TGF beta signaling pathway | 34 | 86 | 5834 | 19747 | 0.029933866 | 1 |
| hsa-miR-660-5p | Endocytosis | 68 | 187 | 5834 | 19747 | 0.025812976 | 1 |
| hsa-miR-660-5p | Toll like receptor signaling pathway | 39 | 105 | 5834 | 19747 | 0.05651642 | 1 |
| hsa-miR-660-5p | Thyroid cancer | 13 | 29 | 5834 | 19747 | 0.058252127 | 1 |
| hsa-miR-660-5p | Fc gamma R mediated phagocytosis | 39 | 97 | 5834 | 19747 | 0.015811658 | 1 |
| hsa-miR-660-5p | SNARE interactions in vesicular transport | 18 | 39 | 5834 | 19747 | 0.020642828 | 1 |
| hsa-miR-660-5p | Long term depression | 31 | 73 | 5834 | 19747 | 0.012611827 | 1 |
| hsa-miR-660-5p | Progesterone mediated oocyte maturation | 35 | 88 | 5834 | 19747 | 0.025436504 | 1 |
| hsa-miR-660-5p | Inositol phosphate metabolism | 22 | 54 | 5834 | 19747 | 0.051713668 | 1 |
| hsa-miR-660-5p | p53 signaling pathway | 28 | 68 | 5834 | 19747 | 0.026708436 | 1 |
| hsa-miR-660-5p | Arrhythmogenic right ventricular cardiomyopathy ARVC | 30 | 74 | 5834 | 19747 | 0.028017892 | 1 |
| hsa-miR-660-5p | Focal adhesion | 76 | 203 | 5834 | 19747 | 0.009166013 | 1 |
| hsa-miR-660-5p | Jak STAT signaling pathway | 58 | 156 | 5834 | 19747 | 0.023864483 | 1 |
| hsa-miR-660-5p | Valine leucine and isoleucine degradation | 19 | 45 | 5834 | 19747 | 0.047463292 | 1 |